{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T21:53:26Z","timestamp":1774130006274,"version":"3.50.1"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy &amp; Behavior"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.yebeh.2022.109032","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T14:12:25Z","timestamp":1671113545000},"page":"109032","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["The potential of intravenous topiramate for the treatment of status epilepticus"],"prefix":"10.1016","volume":"138","author":[{"given":"Wolfgang","family":"L\u00f6scher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugen","family":"Trinka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.yebeh.2022.109032_b0005","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/bcp.12556","article-title":"Pharmacokinetic-pharmacodynamic modelling of intravenous and oral topiramate and its effect on phonemic fluency in adult healthy volunteers","volume":"79","author":"Ahmed","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2022.109032_b0010","doi-asserted-by":"crossref","unstructured":"Apostolakopoulou L, Bosque-Varela P, O'Sullivan C, Rossini F, L\u00f6scher W, Kuchukhidze G, et al. Intravenous topiramate for seizure emergencies \u2013 first in human case report. Epilepsy Behav; 2022. submitted.","DOI":"10.1016\/j.yebeh.2023.109158"},{"issue":"1","key":"10.1016\/j.yebeh.2022.109032_b0015","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.eplepsyres.2008.07.007","article-title":"Resistance to antiepileptic drugs and expression of P-glycoprotein in two rat models of status epilepticus","volume":"82","author":"Bankstahl","year":"2008","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.109032_b0020","first-page":"786","article-title":"Alpha-Lipoic Acid for Treatment of Diabetic Peripheral Neuropathy","volume":"93","author":"Bartkoski","year":"2016","journal-title":"Am Fam Physician"},{"issue":"6","key":"10.1016\/j.yebeh.2022.109032_b0025","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1474-4422(15)00042-3","article-title":"Status epilepticus in adults","volume":"14","author":"Betjemann","year":"2015","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.yebeh.2022.109032_b0030","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40265-016-0672-2","article-title":"Topiramate in the Treatment of Generalized Convulsive Status Epilepticus in Adults: A Systematic Review with Individual Patient Data Analysis","volume":"77","author":"Brigo","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.yebeh.2022.109032_b0035","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.yebeh.2018.07.004","article-title":"Perampanel in the treatment of status epilepticus: A systematic review of the literature","volume":"86","author":"Brigo","year":"2018","journal-title":"Epilepsy Behav"},{"issue":"7","key":"10.1016\/j.yebeh.2022.109032_b0040","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41582-022-00664-3","article-title":"Why won't it stop? The dynamics of benzodiazepine resistance in status epilepticus","volume":"18","author":"Burman","year":"2022","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"10.1016\/j.yebeh.2022.109032_b0045","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1474-4422(06)70374-X","article-title":"Status epilepticus: pathophysiology and management in adults","volume":"5","author":"Chen","year":"2006","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.yebeh.2022.109032_b0050","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/epi.12165","article-title":"Intravenous topiramate: safety and pharmacokinetics following a single dose in patients with epilepsy or migraines taking oral topiramate","volume":"54","author":"Clark","year":"2013","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.yebeh.2022.109032_b0055","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/epi.12134","article-title":"Intravenous topiramate: comparison of pharmacokinetics and safety with the oral formulation in healthy volunteers","volume":"54","author":"Clark","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.109032_b0060","unstructured":"Cloyd JC. Topiramate compositions and methods for their use. Unites States Patent US 2008\/0194519 A1; 2008."},{"issue":"2","key":"10.1016\/j.yebeh.2022.109032_b0065","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1517\/17425250802677826","article-title":"Pharmacodynamic interactions between antiepileptic drugs: preclinical data based on isobolography","volume":"5","author":"Czuczwar","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"10.1016\/j.yebeh.2022.109032_b0070","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1177\/026988119200600312","article-title":"Chemical dissociation of human awareness: focus on non-competitive NMDA receptor antagonists","volume":"6","author":"Domino","year":"1992","journal-title":"J Psychopharmacol"},{"issue":"12","key":"10.1016\/j.yebeh.2022.109032_b0075","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1111\/epi.16382","article-title":"Treatment of refractory and superrefractory status epilepticus with topiramate: A cohort study of 106 patients and a review of the literature","volume":"60","author":"Fechner","year":"2019","journal-title":"Epilepsia"},{"issue":"11","key":"10.1016\/j.yebeh.2022.109032_b0080","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/j.0013-9580.2004.26404.x","article-title":"Synergism between topiramate and budipine in refractory status epilepticus in the rat","volume":"45","author":"Fisher","year":"2004","journal-title":"Epilepsia"},{"issue":"2-3","key":"10.1016\/j.yebeh.2022.109032_b0085","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.eplepsyres.2006.07.014","article-title":"The combination of topiramate and diazepam is partially neuroprotective in the hippocampus but not antiepileptogenic in the lithium-pilocarpine model of temporal lobe epilepsy","volume":"72","author":"Fran\u00e7ois","year":"2006","journal-title":"Epilepsy Res"},{"issue":"6","key":"10.1016\/j.yebeh.2022.109032_b0090","doi-asserted-by":"crossref","first-page":"549","DOI":"10.12809\/hkmj208488","article-title":"Ketamine use for super-refractory status epilepticus in children","volume":"26","author":"Fung","year":"2020","journal-title":"Hong Kong Med J"},{"issue":"1","key":"10.1016\/j.yebeh.2022.109032_b0095","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5698\/1535-7597-16.1.48","article-title":"Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society","volume":"16","author":"Glauser","year":"2016","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.yebeh.2022.109032_b0100","unstructured":"Herman TF, Santos C. First Pass Effect. StatPearls - NCBI Bookshelf; 2022."},{"key":"10.1016\/j.yebeh.2022.109032_b0105","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2165\/11633090-000000000-00000","article-title":"Topiramate as an adjunctive treatment in patients with refractory status epilepticus: an observational cohort study","volume":"26","author":"Hottinger","year":"2012","journal-title":"CNS Drugs"},{"issue":"9","key":"10.1016\/j.yebeh.2022.109032_b0110","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s40263-016-0371-2","article-title":"(S)-Ketamine in Refractory and Super-Refractory Status Epilepticus: A Retrospective Study","volume":"30","author":"H\u00f6fler","year":"2016","journal-title":"CNS Drugs"},{"issue":"Suppl 2","key":"10.1016\/j.yebeh.2022.109032_b0115","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/epi.14480","article-title":"Intravenous ketamine in status epilepticus","volume":"59","author":"H\u00f6fler","year":"2018","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.yebeh.2022.109032_b0120","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/cpdd.1107","article-title":"Intravenous Perampanel as an Interchangeable Alternative to Oral Perampanel: A Randomized, Crossover, Phase I Pharmacokinetic and Safety Study","volume":"11","author":"Hussein","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"Suppl 2","key":"10.1016\/j.yebeh.2022.109032_b0125","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/epi.14482","article-title":"Mechanisms of status epilepticus: a-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor hypothesis","volume":"59","author":"Joshi","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.109032_b0130","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.yebeh.2015.04.065","article-title":"Incidence and mortality of super-refractory status epilepticus in adults","volume":"49","author":"Kantanen","year":"2015","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.109032_b0135","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.eplepsyres.2017.03.009","article-title":"Long-term outcome of refractory status epilepticus in adults: A retrospective population-based study","volume":"133","author":"Kantanen","year":"2017","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.109032_b0140","doi-asserted-by":"crossref","first-page":"106413","DOI":"10.1016\/j.yebeh.2019.07.014","article-title":"Incidence of the different stages of status epilepticus in Eastern Finland: A population-based study","volume":"101","author":"Kantanen","year":"2019","journal-title":"Epilepsy Behav"},{"issue":"12","key":"10.1016\/j.yebeh.2022.109032_b0145","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1111\/epi.13584","article-title":"Costs and cost-driving factors for acute treatment of adults with status epilepticus: A multicenter cohort study from Germany","volume":"57","author":"Kortland","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.109032_b0150","first-page":"553","article-title":"Effect of topiramate on the kainate-induced status epilepticus, lipid peroxidation and immunoreactivity of rats","volume":"56","author":"Kubera","year":"2004","journal-title":"Pol J Pharmacol"},{"issue":"12","key":"10.1016\/j.yebeh.2022.109032_b0155","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.0013-9580.2004.13504.x","article-title":"The mechanism of neuroprotection by topiramate in an animal model of epilepsy","volume":"45","author":"Kudin","year":"2004","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.yebeh.2022.109032_b0160","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/epi.14607","article-title":"Epidemiology of status epilepticus in adults: A population-based study on incidence, causes, and outcomes","volume":"60","author":"Leitinger","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.109032_b0165","doi-asserted-by":"crossref","first-page":"106720","DOI":"10.1016\/j.yebeh.2019.106720","article-title":"Epidemiology of status epilepticus in adults: Apples, pears, and oranges - A critical review","volume":"103","author":"Leitinger","year":"2020","journal-title":"Epilepsy Behav"},{"issue":"6","key":"10.1016\/j.yebeh.2022.109032_b0170","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/jcph.646","article-title":"Pharmacokinetic-Pharmacodynamic Modeling of Intravenous and Oral Topiramate and Its Effect on the Symbol-Digit Modalities Test in Adult Healthy Volunteers","volume":"56","author":"Lim","year":"2016","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.yebeh.2022.109032_b0175","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/biom.12817","article-title":"Quantifying publication bias in meta-analysis","volume":"74","author":"Lin","year":"2018","journal-title":"Biometrics"},{"issue":"2","key":"10.1016\/j.yebeh.2022.109032_b0180","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.xphs.2020.10.026","article-title":"Cyclodextrins in Parenteral Formulations","volume":"110","author":"Loftsson","year":"2021","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.yebeh.2022.109032_b0185","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.yebeh.2015.02.027","article-title":"Single versus combinatorial therapies in status epilepticus: Novel data from preclinical models","volume":"49","author":"L\u00f6scher","year":"2015","journal-title":"Epilepsy Behav"},{"issue":"9","key":"10.1016\/j.yebeh.2022.109032_b0190","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s40263-021-00827-8","article-title":"The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond","volume":"35","author":"L\u00f6scher","year":"2021","journal-title":"CNS Drugs"},{"issue":"15","key":"10.1016\/j.yebeh.2022.109032_b0195","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.2165\/00003495-200767150-00008","article-title":"Topiramate: a review of its use in the treatment of epilepsy","volume":"67","author":"Lyseng-Williamson","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.yebeh.2022.109032_b0200","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/(SICI)1096-9888(199801)33:1<85::AID-JMS612>3.0.CO;2-R","article-title":"In vivo microdialysis and liquid chromatography\/thermospray mass spectrometry of the novel anticonvulsant 2,3:4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate (topiramate) in rat brain fluid","volume":"33","author":"Masucci","year":"1998","journal-title":"J Mass Spectrom"},{"issue":"4","key":"10.1016\/j.yebeh.2022.109032_b0205","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1528-1167.2007.00987.x","article-title":"Age-dependent effects of topiramate on the acquisition and the retention of rapid kindling","volume":"48","author":"Mazarati","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.109032_b0210","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J Basic Clin Pharm"},{"issue":"1-2","key":"10.1016\/j.yebeh.2022.109032_b0215","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0006-8993(99)01615-7","article-title":"Topiramate reduces neuronal injury after experimental status epilepticus","volume":"837","author":"Niebauer","year":"1999","journal-title":"Brain Res"},{"key":"10.1016\/j.yebeh.2022.109032_b0220","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/nyas.13147","article-title":"Benzodiazepine-refractory status epilepticus: pathophysiology and principles of treatment","volume":"1378","author":"Niquet","year":"2016","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.yebeh.2022.109032_b0225","doi-asserted-by":"crossref","first-page":"104537","DOI":"10.1016\/j.nbd.2019.104537","article-title":"Rational polytherapy in the treatment of cholinergic seizures","volume":"133","author":"Niquet","year":"2020","journal-title":"Neurobiol Dis"},{"issue":"4","key":"10.1016\/j.yebeh.2022.109032_b0230","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1528-1167.2006.00504.x","article-title":"Comparison of brain extracellular fluid, brain tissue, cerebrospinal fluid, and serum concentrations of antiepileptic drugs measured intraoperatively in patients with intractable epilepsy","volume":"47","author":"Rambeck","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.109032_b0235","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1124\/jpet.103.057091","article-title":"Neuroprotective properties of topiramate in the lithium-pilocarpine model of epilepsy","volume":"308","author":"Rigoulot","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.yebeh.2022.109032_b0240","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a022780","article-title":"Mechanisms of Action of Antiseizure Drugs and the Ketogenic Diet","volume":"6","author":"Rogawski","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.yebeh.2022.109032_b0245","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.yebeh.2015.04.005","article-title":"Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit","volume":"49","author":"Rohracher","year":"2015","journal-title":"Epilepsy Behav"},{"issue":"Suppl 2","key":"10.1016\/j.yebeh.2022.109032_b0250","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/epi.14494","article-title":"Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit: A single-center audit of 30 patients","volume":"59","author":"Rohracher","year":"2018","journal-title":"Epilepsia"},{"issue":"11","key":"10.1016\/j.yebeh.2022.109032_b0255","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s40263-018-0569-6","article-title":"Ketamine for Refractory Status Epilepticus: A Systematic Review","volume":"32","author":"Rosati","year":"2018","journal-title":"CNS Drugs"},{"issue":"Suppl 1","key":"10.1016\/j.yebeh.2022.109032_b0260","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1111\/j.1528-1157.2000.tb02163.x","article-title":"An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action","volume":"41","author":"Shank","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.109032_b0265","unstructured":"Sheskey PJ, Hancock BC, Moss GP, Goldfarb DJ. Handbook of pharmaceutical excipients. 9th ed. London, U.K.: Pharmaceutical Press; 2020."},{"key":"10.1016\/j.yebeh.2022.109032_b0270","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/j.1528-1167.2008.01706_3.x","article-title":"The drug treatment of status epilepticus in Europe: consensus document from a workshop at the first London Colloquium on Status Epilepticus","volume":"49","author":"Shorvon","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.109032_b0275","doi-asserted-by":"crossref","first-page":"107966","DOI":"10.1016\/j.neuropharm.2020.107966","article-title":"Mechanisms of Action of Currently Used Antiseizure Drugs","volume":"168","author":"Sills","year":"2020","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.yebeh.2022.109032_b0280","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/0192623307310945","article-title":"Cyclodextrins","volume":"36","author":"Stella","year":"2008","journal-title":"Toxicol. Pathol."},{"issue":"4","key":"10.1016\/j.yebeh.2022.109032_b0285","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/ane.13061","article-title":"Perampanel for treatment of status epilepticus in Austria, Finland, Germany, and Spain","volume":"139","author":"Strzelczyk","year":"2019","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"10.1016\/j.yebeh.2022.109032_b0290","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1203\/01.pdr.0000196333.16608.30","article-title":"Treatment of experimental status epilepticus in immature rats: dissociation between anticonvulsant and antiepileptogenic effects","volume":"59","author":"Suchomelova","year":"2006","journal-title":"Pediatr Res"},{"key":"10.1016\/j.yebeh.2022.109032_b0295","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1212\/WNL.0000000000000009","article-title":"Anesthetic drugs in status epilepticus: risk or rescue? A 6-year cohort study","volume":"82","author":"Sutter","year":"2014","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.yebeh.2022.109032_b0300","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1212\/01.WNL.0000042783.86439.27","article-title":"The use of topiramate in refractory status epilepticus","volume":"60","author":"Towne","year":"2003","journal-title":"Neurology"},{"issue":"13","key":"10.1016\/j.yebeh.2022.109032_b0305","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s40265-015-0454-2","article-title":"Pharmacotherapy for Status Epilepticus","volume":"75","author":"Trinka","year":"2015","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.yebeh.2022.109032_b0310","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/epi.13121","article-title":"A definition and classification of status epilepticus\u2013Report of the ILAE Task Force on Classification of Status Epilepticus","volume":"56","author":"Trinka","year":"2015","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.yebeh.2022.109032_b0315","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1517\/14656566.2016.1127354","article-title":"Pharmacologic treatment of status epilepticus","volume":"17","author":"Trinka","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.yebeh.2022.109032_b0320","first-page":"559","article-title":"Management of Status Epilepticus, Refractory Status Epilepticus, and Super-refractory Status Epilepticus","volume":"28","author":"Trinka","year":"2022","journal-title":"Continuum (Minneap. Minn.)"},{"key":"10.1016\/j.yebeh.2022.109032_b0325","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3389\/fvets.2016.00107","article-title":"Intravenous Topiramate: Pharmacokinetics in Dogs with Naturally Occurring Epilepsy","volume":"3","author":"Vuu","year":"2016","journal-title":"Front Vet Sci"},{"issue":"Suppl 8","key":"10.1016\/j.yebeh.2022.109032_b0330","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1528-1167.2011.03243.x","article-title":"Rational polytherapy in the treatment of acute seizures and status epilepticus","volume":"52","author":"Wasterlain","year":"2011","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.yebeh.2022.109032_b0335","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/jebm.12356","article-title":"Sample sizes and statistical methods in interventional studies on individuals with spinal cord injury: A systematic review","volume":"12","author":"Zimmermann","year":"2019","journal-title":"J Evid Based Med"},{"key":"10.1016\/j.yebeh.2022.109032_bib336","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.3390\/ijms22052264","article-title":"Anticonvulsant effects of topiramate and lacosamide on pilocarpine-induced status epilepticus in rats: A role of reactive oxygen species and inflammation","volume":"22","author":"Shishmanova-Doseva","year":"2021","journal-title":"Int. J. Mol. Sci."}],"container-title":["Epilepsy &amp; Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505022004814?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505022004814?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:49:10Z","timestamp":1761504550000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505022004814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":68,"alternative-id":["S1525505022004814"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2022.109032","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The potential of intravenous topiramate for the treatment of status epilepticus","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2022.109032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109032"}}